|
注册号: Registration number: |
ChiCTR2500114707 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-16 17:49:00 |
|
注册时间: Date of Registration: |
2025-12-16 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
功能性运动矩阵对乳腺癌患者抗肿瘤治疗相关性心脏毒性方面的影响研究 |
|
Public title: |
A Study on the Effect of an Exercise Program on Protecting Heart Health in Breast Cancer Patients During Anti-Cancer Treatment |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
功能性运动矩阵对乳腺癌患者抗肿瘤治疗相关性心脏毒性方面的影响研究 |
|
Scientific title: |
Effects of a Functional Exercise Matrix Program on Cardiotoxicity in Breast Cancer Patients Undergoing Antitumor Therapy: A Randomized Controlled Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘春玉 |
研究负责人: |
刘春玉 |
|
Applicant: |
Liu Chunyu |
Study leader: |
Liu Chunyu |
|
申请注册联系人电话: Applicant telephone: |
+86 184 0355 1442 |
研究负责人电话:
Study leader's |
+86 184 0355 1442 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liuchunyu0619@163.com |
研究负责人电子邮件: Study leader's E-mail: |
liuchunyu0619@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
海南省海口市秀英区西秀镇长滨西四街6号 |
研究负责人通讯地址: |
海南省海口市秀英区西秀镇长滨西四街6号 |
|
Applicant address: |
6 Changbin Xisi Street, Xixiu Town, Xiuying District, Haikou City, Hainan Province |
Study leader's address: |
6 Changbin Xisi Street, Xixiu Town, Xiuying District, Haikou City, Hainan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
海南省肿瘤医院康复医学科 |
||
|
Applicant's institution: |
Department of Rehabilitation Medicine, Hainan Cancer Hospital |
||
|
研究负责人所在单位: |
海南省肿瘤医院康复医学科 |
||
|
Affiliation of the Leader: |
Department of Rehabilitation Medicine, Hainan Cancer Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
EC-2023-030-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
海南省肿瘤医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Scientific Research Ethics Committee of Hainan Cancer Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-02-28 00:00:00 | ||
|
伦理委员会联系人: |
柳丽颖 |
||
|
Contact Name of the ethic committee: |
Liu Liying |
||
|
伦理委员会联系地址: |
海南省海口市秀英区西秀镇长滨西四街6号 |
||
|
Contact Address of the ethic committee: |
6 Changbin Xisi Street, Xixiu Town, Xiuying District, Haikou City, Hainan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 898 3662 7719 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
HNZLKYLL@163.com |
|
研究实施负责(组长)单位: |
海南省肿瘤医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hainan Cancer Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
海南省海口市秀英区西秀镇长滨西四街6号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
6 Changbin Xisi Street, Xixiu Town, Xiuying District, Haikou City, Hainan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2023年海南省自然科学基金青年基金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sponsored by the 2023 Hainan Provincial Natural Science Foundation Youth Fund Project |
||||||||||||||||||||||
|
研究疾病: |
乳腺癌 |
||||||||||||||||||||||
|
Target disease: |
Breast cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本研究拟采用多组分运动类型—功能性运动矩阵、高强度间歇训练模式干预接受蒽环类药物的乳腺癌患者,开展前瞻性病例系列研究。通过观察患者左心室射血分数与生物标志物的变化,探讨功能性运动矩阵在预防和减轻乳腺癌患者心脏毒性的安全性和有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study proposes a prospective case series to investigate a multi-component exercise intervention—comprising a Functional Exercise Matrix and High-Intensity Interval Training—in breast cancer patients receiving anthracycline-based therapy. The safety and efficacy of the Functional Exercise Matrix in preventing and attenuating cardiotoxicity will be evaluated by monitoring changes in left ventricular ejection fraction and relevant biomarkers. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.对持续锻炼有任何的局限性,心肺运动测试禁忌症者,患有胸廓及脊柱畸形、呼吸系统疾病等影响超声图像质量者; 2.有增加蒽环类药物心脏毒性风险的因素(糖尿病、血脂异常、高血压、吸烟,饮酒,BMI>35 kg / m^2); 3.孕妇及哺乳期女性; 4.有进行其他类型运动训练或药物保护的研究; 5.预期生存期<24个月者,营养不良(BMI<18 kg/m^2)或前3个月体重下降10%者; 6.既往有心血管疾病病史如冠心病、心肌病、心脏瓣膜疾病、心律失常等; 7.接受过≥2种降压药物; 8.其他:严重贫血(血红蛋白< 8g /dL)不能通过输血和/或补充铁和/或维生素缺乏症来纠正;急性感染。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Any contraindication to sustained exercise or cardiopulmonary exercise testing; presence of conditions affecting ultrasound image quality, such as thoracic or spinal deformities or respiratory diseases. 2. Factors increasing the risk of anthracycline-induced cardiotoxicity (e.g., diabetes, dyslipidemia, hypertension, smoking, alcohol consumption, BMI > 35 kg/m²). 3. Pregnant or lactating women. 4. Previous history of chemotherapy or radiotherapy; concurrent participation in other interventional studies involving exercise training or cardioprotective drugs. 5. Expected survival < 24 months; malnutrition (BMI < 18.5 kg/m²) or weight loss > 10% within the previous 3 months. 6. History of cardiovascular diseases, such as coronary artery disease, cardiomyopathy, valvular heart disease, or arrhythmia. 7. Use of >=2 classes of antihypertensive medications. 8. Others: Severe anemia (hemoglobin < 8 g/dL) not correctable by transfusion and/or supplementation of iron/vitamin deficiencies; active infection. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-31 00:00:00至 To 2026-02-28 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-04-10 00:00:00 至 To 2026-02-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究公开发表后半年,邮件联系研究负责人合理获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the publication of the research, contact the research leader via email to obtain reasonable information. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
未说明 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Not stated |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |